Cielo Piano inferiore Straripante idarucizumab clinical trial Collegamenti singolo divario
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects - ScienceDirect
Usefulness of initial plasma dabigatran concentration to predict rebound after reversal | Haematologica
PDF) Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study - Research and Practice in Thrombosis and Haemostasis
FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate) | Business Wire
Idarucizumab | Circulation
Design of the Reversal Effects of Idarucizumab on Active Dabigatran... | Download Scientific Diagram
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab: Plenty of optimism, not enough science - First10EM
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination - Stephan Glund, Guanfa Gan, Viktoria Moschetti, Paul Reilly, Markus Honickel, Oliver Grottke, Joanne Van Ryn,
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Idarucizumab, the Sequel – Emergency Medicine Literature of Note
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study - Yasaka - 2017 - Research and Practice in Thrombosis and Haemostasis - Wiley Online Library
Boehringer Ingelheim submits applications for approval of Idarucizumab, an anti-anticoagulant - Labiotech.eu
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Ef
Idarucizumab for Dabigatran Reversal – The Bottom Line
Medicina | Free Full-Text | Effectiveness and Safety of Dabigatran Reversal with Idarucizumab in the Taiwanese Population: A Comparison Based on Eligibility for Inclusion in Clinical Trials
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study | SpringerLink
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis - MPR
Idarucizumab for Reversal of Dabigatran – Core EM
Praxbind Full Prescribing Information, Dosage & Side Effects | MIMS Thailand
Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre - Wheeler - 2019 - Internal Medicine Journal - Wiley Online Library
Clinical Evidence | Praxbind® (idarucizumab)
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet